Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Status Completed

Clinical Trial Summary

There are limited but encouraging results supporting the use of dalfampridine in patients with hereditary spastic paraplegia. The investigators aimed to investigate the effects of dalfampridine on walking speed, muscle length, spasticity, functional strength, and functional mobility in patients with hereditary spastic paraplegia. In this triple-blinded, randomized, placebo-controlled trial, 4 patients with hereditary spastic paraplegia received dalfampridine (10 mg twice daily) plus physiotherapy (2 times per week), and 4 patients received placebo plus physiotherapy for a total duration of 8 weeks. The assessor and treating physiotherapists, and patients were masked to the group allocation. The primary outcome was Timed 25-foot Walk Test at the end of the 8-week treatment. The secondary outcome measures were functional mobility, functional muscle strength, muscle length, and spasticity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05613114
Study type	Interventional
Source	European University of Lefke
Contact
Status	Completed
Phase	N/A
Start date	August 3, 2020
Completion date	March 12, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06117020` - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals	Phase 1
Completed	`NCT05373082` - Identification of Modifying Factors in Hereditary Spastic Paraplegia
Recruiting	`NCT03981276` - Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Terminated	`NCT02859428` - Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
Completed	`NCT03104088` - Studying Cognition in SPG4
Recruiting	`NCT05848271` - Natural History Study of Patients With HPDL Mutations
Completed	`NCT02604186` - Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia	Phase 2/Phase 3
Completed	`NCT04912609` - Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
Recruiting	`NCT03206190` - The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4	N/A
Completed	`NCT03627416` - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy	N/A
Recruiting	`NCT04875416` - Phenotype, Genotype and Biomarkers 2
Withdrawn	`NCT05411627` - A Pilot Study of Shockwave Therapy in HSP	N/A
Completed	`NCT03961906` - Physiotherapy in Hereditary Spastic Paraplegia	Phase 2
Completed	`NCT05767268` - Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
Completed	`NCT02852278` - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed	`NCT04180098` - Improving Gait Adaptability in Hereditary Spastic Paraplegia	N/A
Completed	`NCT00023075` - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis	N/A
Recruiting	`NCT04712812` - Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Recruiting	`NCT05354622` - Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Enrolling by invitation	`NCT02327845` - Phenotype, Genotype & Biomarkers in ALS and Related Disorders